Sanofi India shares slipped more than 2% in early trade on Friday after the pharmaceutical major posted disappointing Q1 results for the financial year. The company’s revenue and operating margins declined year-on-year, sparking negative investor sentiment.
Q1 FY26 Financial Highlights (YoY)
In the quarter ended June 2025, Sanofi India reported a 12.4% drop in consolidated revenue to ₹406 crore, down from ₹464 crore in the same period last year. EBITDA also took a hit, falling 18% to ₹94.9 crore from ₹116 crore. Operating margins came in lower at 23.4%, compared to 25% a year ago.
Despite the revenue and EBITDA decline, net profit rose significantly to ₹69.5 crore, compared to just ₹10.3 crore in Q1 FY25.
Market Reaction
Sanofi India opened the day at ₹5,801 and touched an intraday low of ₹5,669, slipping over 2% from its previous close of ₹5,825. The stock continues to trade below its 52-week high of ₹7,600 but remains well above the 52-week low of ₹4,902.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
